Phase 0 - Microdosing strategy in clinical trials
2008

Microdosing Strategy in Clinical Trials

publication Evidence: moderate

Author Information

Author(s): Rani P. Usha, Naidu M. U.

Primary Institution: Nizam's Institute of Medical Sciences, Hyderabad, India

Hypothesis

Microdosing will help to reduce or replace the extensive animal testing of compounds for kinetics.

Conclusion

Microdosing may help both patients and the pharma industry with earlier availability of new test medication and reduced attrition of compounds at later stages of drug development.

Supporting Evidence

  • Microdosing requires much less drug than traditional methods, making it safer.
  • Microdosing can reduce the time and cost of early drug development.
  • Microdosing may help identify which drugs are likely to succeed in later trials.

Takeaway

Microdosing is like giving a tiny taste of medicine to see how the body reacts without making people sick. It helps scientists find out which medicines might work best before giving larger doses.

Methodology

Microdosing uses extremely low doses of drugs to study their pharmacokinetic profiles in humans.

Limitations

Microdosing may not accurately predict how a drug behaves at higher doses, especially for drugs with complex pharmacokinetics.

Digital Object Identifier (DOI)

10.4103/0253-7613.45147

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication